A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy

This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated.

NCT Number	NCT07560020
Lead Sponsor	RyCarma Therapeutics, Inc.
Conditions	Autosomal Dominant RYR1-Related Myopathy
Enrollment	28 participants
Start Date	2026-07-01
Primary Completion	2027-08-27 (estimated)
Study Completion	2028-08-27 (estimated)
Updated on ClinicalTrials.gov	2026-07-15